LC-MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-07. Anything still debated is marked as such rather than presented as settled.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
== Resistance == Resistance is a major cause of treatment failure in chemotherapeutic drugs and results in cancer cell survival despite exposure to such toxins. Broadly, resistance types can be classified based on the points at which cancer cells are no longer susceptible to the effects of chemotherapeutic drugs. One form of resistance is known as primary, or natural resistance, where cancer cells possess innate mechanisms that allow them to be unresponsive to chemotherapeutic drug exposure from the very beginning of its administration. Contrarily, acquired resistance is characterized by an initial, brief period of cancer cell susceptibility to the applied chemotherapeutic agent, followed by later stages of poor drug response. Despite these differences between the points at which resistance emerges, either form can result in what is known as multi-drug resistance, essentially allowing cancer cells to evade the effects of both similarly and differently functioning chemotherapeutic drugs regardless of their previous exposure to them. There are various contributors to emerging resistance in cancer, one of which is the presence of small pumps on the surface of cancer cells that actively transport concentrations of chemotherapy drugs from inside the cell to the outside, otherwise known as efflux pumps. However, these pumps are not unique characteristics of cancer cells whereas in normal functioning cells, efflux pumps are actually engaged in life-sustaining processes that help avoid the accumulation of waste and toxin absorption in the body.
Once a drug's bioavailability has been established it is possible to calculate the changes that need to be made to its dosage in order to reach the required blood plasma levels. Bioavailability is, therefore, a mathematical factor for each individual drug that influences the administered dose. It is possible to calculate the amount of a drug in the blood plasma that has a real potential to bring about its effect using the formula:
== Natural occurrence == Myristicin can be found in the essential oil of nutmeg, black pepper, kawakawa, and many members of the Umbelliferae family, including anise, carrots, parsley, celery, dill, and parsnip. Trace amounts have also been isolated from a variety of plant species including Ridolfia segetum (harvest fennel), species of the Oenanthe genus (water dropworts), some species of the Lamiaceae family (mint family), Cinnamomum glanduliferum (Nepal camphor tree), and Piper mullesua ("Hill Pepper"). Depending on the conditions of growth and storage of the plant, a high quality nutmeg (Myristica fragrans) seed can contain up to 13 mg of myristicin per 1 gram.
=== Dietary === In the United States, many people's diets are excessively high in calories, often due to fast food and sugary beverages. Individuals with obesity may consume more calories before feeling full, experience hunger more quickly, or eat in response to stress or anxiety. Per the USDA's Dietary Guidelines for Americans, 2020-2025, most Americans do not follow a healthy dietary pattern. Few individuals being tested for nutrient levels would be able to meet them without the use of fortification or enrichment. Americans eat an abundance of fast food. 36.6% of adults consume fast food on a given day and 2 out of 3 people consume fast food at least once a week. While the negative effects of fast food, such as lack of nutritional value and high amounts of calories, are widely known, fast food remains popular for its convenience, specifically because it is time-efficient and cheap. Quantity of food consumption plays an important role as well. A study shows a significant increase in food portion sizes of marketplace products since the 1970s that exceed the federal standards for dietary guidance. Reasons for this increase include the expansion of the food industry since the seventies, marketing strategies, and customer demand. Extreme differences in portion sizes between the same menu items of the same franchises have also been observed. In some instances, American food portion sizes are as much as double the size of their British counterparts.
Iron-deficiency anemia may be present without a person experiencing symptoms. It tends to develop slowly; therefore, the body has time to adapt, and the disease often goes unrecognized for some time. If symptoms present, patients may present with the sign of pallor (reduced oxyhemoglobin in skin or mucous membranes), and the symptoms of feeling tired, weak, dizziness, lightheadedness, poor physical exertion, headaches, decreased ability to concentrate, cold hands and feet, cold sensitivity, increased thirst and confusion. None of these symptoms (or any of the others below) are sensitive or specific. In severe cases, shortness of breath can occur. Pica may also develop; of which consumption of ice, known as pagophagia, has been suggested to be the most specific for iron deficiency anemia. Other possible symptoms and signs of iron-deficiency anemia include:
Sources: en.wikipedia.org
=== Wars, battles, and revolts === In Spain, Riego's Rebellion was critical on the military balance in South America because it enabled Rioplatense, Chilean, and Colombian revolutionaries to converge against the Viceroy of Peru. In New Spain, Agustín de Iturbide echoed Riego's revolt, beginning a process that led to Mexican independence seven months later.
Maulana Shabbir Ahmad Usmani, a respected Deobandi alim (scholar) who held the position of Shaykh al-Islam in Pakistan in 1949, and Maulana Mawdudi of Jamaat-i-Islami played key roles in advocating for an Islamic constitution. Mawdudi insisted that the Constituent Assembly declare the "supreme sovereignty of God" and the supremacy of the shariah in Pakistan. The efforts of Jamaat-i-Islami and the ulama led to the passage of the Objectives Resolution in March 1949. This resolution, described by Liaquat Ali Khan as the second most significant step in Pakistan's history, affirmed that "sovereignty over the entire universe belongs to God Almighty alone and the authority which He has delegated to the State of Pakistan through its people for being exercised within the limits prescribed by Him is a sacred trust". It was later included as a preamble to the constitutions of 1956, 1962, and 1973. Democracy faced setbacks due to the martial law imposed by President Iskander Mirza, who was succeeded by General Ayub Khan. After adopting a presidential system in 1962, Pakistan witnessed significant growth until the second war with India in 1965, resulting in an economic downturn and widespread public discontent in 1967. In 1969, President Yahya Khan consolidated control, but faced a devastating cyclone in East Pakistan resulting in 500,000 deaths. In 1970, Pakistan conducted its first democratic elections since independence, intending to transition from military rule to democracy.
== Side effects == The most common adverse effects in studies were upper respiratory tract infection, headache, nausea, and diarrhea. The most common side effects in clinical trials were nasopharyngitis, nausea, headaches, herpes simplex (including oral herpes, ophthalmic herpes, herpes dermatitis and genital herpes), and increase in blood creatine phosphokinase. Abrocitinib can cause serious infections, malignancy, major cardiac events, thrombosis and other laboratory abnormalities including thrombocytopenia, lymphopenia, and lipid elevations. However, according to clinical data, Abrocitinib is well tolerated. The total adverse reactions were not statistically different between the placebo and the dose of 100 mg of abrocitinib. However, it was slightly higher for the dose of 200 mg of abrocitinib. Symptoms such as acne, headache, and nausea, appeared in the first two weeks of starting abrocitinib, and it was not necessary to interrupt the treatment. In general, the AE frequency of abrocitinib was the same or a little bit higher than in case of placebo or dupilumab.
While the "ness team" began moving to Bawdsey, the Orfordness site remained in use. This proved useful during one demonstration when the new system recently completed at Bawdsey failed. The next day, Robert Hanbury-Brown and the new recruit Gerald Touch started up the Orfordness system and were able to run the demonstrations from there. The Orfordness site was not closed until 1937.
=== American Indian === Alaska Native Brotherhood Brotherhood of North American Indians - Founded by Richard C. Adams of the Delaware Tribe of Oklahoma on December 5, 1911, in Washington, DC. Membership was open to people of Indian blood. Those married to Indians, the President of the United States, the Commissioner of Indian Affairs, and other public officials could become honorary members, without vote. The Brotherhood advocated giving Indians the right to vote and granting them citizenship, the placement of Indian children in public school, more Indians working at the Bureau of Indian Affairs, and Indian representation in Congress. The national convention in Washington would elect 20 national chiefs, a Great Sachem, a Chief Historian, and a Great Chaplain. The Brotherhood collapsed in 1913. Daughters of Sacajawea - Organized in the 1920s, possibly as the New York City chapter of the Teepee Order of America. Both groups were founded by Red Fox Francis St. James, which created difficulties, as he was intolerant of Catholics and blacks, so Catholic Indians and those that had black ancestry opposed his groups. In 1926, Princess Chinquilla, a Cheyenne woman, was the "Great Sacajawea" of the group and worked with St. James to create an Indian cultural center in New York, but the project fell through. Loyal Order of Tecumseh - Founded by Arthur C. Parker as a society within the Society of American Indians to provide a common ground for those with greater and lesser degrees of Indian blood.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.